Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
NCT ID: NCT06996093
Last Updated: 2025-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
2508 participants
INTERVENTIONAL
2025-06-02
2034-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer
NCT07213206
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344793
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
NCT02980965
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
NCT06176534
Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery
NCT00963729
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study, patient eligible will be randomized into either standard endocrine therapy plus CDK4/6 inhibitor without chemotherapy or standard endocrine therapy plus CDK4/6 inhibitor following 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy.The safety and efficacy of each group will be assessed through invasive disease free survival (iDFS), disease-free survival (DFS), distant disease free survival (DDFS), overall survival (OS) and adverse effects (AE) as graded by Common Terminology Criteria for Adverse Events (CTCAE) 5.0 and patient reported outcome (PRO).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm #1: Endocrine+CDK4/6i
aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor without chemotherapy
aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
Arm #2: TC*4-Endocrine+CDK4/6i
4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy, followed by aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG performance status 0-1;
* Early-stage breast cancer, with postoperative pathology confirming invasive carcinoma, HR-positive and HER2-negative (In this study, HR-positive is defined as: ER-positive by IHC with \>10% tumor cells staining positive; HER2-negative defined as HER2 0-1+ by IHC or HER2++ with negative FISH result, without amplification);
* Postoperative pathological stage pT2N0M0 and:
Histological grade 3, or Histological grade 2 with Ki67 ≥ 20% or high-risk multigene assay results;
* No prior neoadjuvant therapy received;
* Good postoperative recovery, with randomization occurring no more than 8 weeks after surgery;
* Normal function of major organs, meeting the following criteria:
Hematological tests must meet: HB ≥90 g/L (no transfusion within 14 days); ANC ≥1.5×10⁹/L; PLT ≥100×10⁹/L; Biochemical tests must meet: TBIL ≤1.5×ULN (upper limit of normal); ALT and AST ≤3×ULN; serum Cr ≤1.5×ULN;
* Contraception required for male participants and women of childbearing potential during treatment;
* Participants voluntarily enroll in the study, sign informed consent, demonstrate good compliance, and cooperate with follow-up.
Exclusion Criteria
* Metastasis at any site;
* Clinical or imaging suspicion of malignancy in the contralateral breast requiring biopsy (unless ruled out);
* Prior neoadjuvant therapy, including chemotherapy, radiotherapy, or endocrine therapy;
* Use of tamoxifen, raloxifene, or aromatase inhibitors (AIs) for breast cancer risk reduction ("chemoprevention") and/or osteoporosis treatment within the past 2 years;
* History of other malignancies within the past 5 years (except basal cell carcinoma of the skin or carcinoma in situ of the cervix), including contralateral breast cancer;
* Concurrent participation in another clinical trial;
* Severe systemic diseases and/or uncontrolled infections that preclude study participation;
* Severe cardiovascular or cerebrovascular events within 6 months before randomization (e.g., unstable angina, chronic heart failure, uncontrolled hypertension \>150/90 mmHg, myocardial infarction, or stroke);
* Known hypersensitivity to the study drugs;
* Men and women of childbearing potential unwilling to use contraception during treatment and for 8 weeks after treatment completion;
* Pregnant or lactating women;
* Positive pregnancy test before study drug administration (for women of childbearing potential);
* Psychiatric disorders, cognitive impairment, or inability to comprehend the trial protocol, adverse effects, or comply with study procedures and follow-up (requires systematic evaluation before enrollment);
* Individuals lacking personal freedom or legal capacity for independent civil conduct.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhimin Shao
Professor (MD, PhD)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhimin Shao, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCHBCC-N087
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.